Why the study?
Does a combined percutaneous approach (TAVR+PCI) improve outcomes compared to a surgical approach (SAVR+CABG) in patients with severe AS and concomitant CAD?
Does a combined percutaneous approach (TAVR+PCI) improve outcomes compared to a surgical approach (SAVR+CABG) in patients with severe AS and concomitant CAD?
In patients with severe AS and CAD, TAVR+PCI may offer lower index admission mortality and MACE but higher 30-day complications compared to SAVR+CABG.
Answers are grounded in this paper and cite their sources.
Should not yet alter management of severe AS with CAD; hypothesis-generating for percutaneous versus surgical strategies pending randomized trials.
In selected patients with severe AS and concomitant CAD, a combined percutaneous approach (TAVR+PCI) compared with SAVR+CABG may confer a lower risk of MACE and mortality during index admission but a higher incidence of 30-day complications.
No takes yet. Share an insight, caveat, or question.
Ullah et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: